HCV综合护理:一项随机试验,以增加直接作用抗病毒药物的治疗起始和SVR。

IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
International Journal of Hepatology Pub Date : 2017-01-01 Epub Date: 2017-07-27 DOI:10.1155/2017/5834182
Erik J Groessl, Lin Liu, Marisa Sklar, Samuel B Ho
{"title":"HCV综合护理:一项随机试验,以增加直接作用抗病毒药物的治疗起始和SVR。","authors":"Erik J Groessl,&nbsp;Lin Liu,&nbsp;Marisa Sklar,&nbsp;Samuel B Ho","doi":"10.1155/2017/5834182","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Psychiatric or substance use disorders are barriers to successful HCV antiviral treatment. In a randomized, controlled trial (RCT), the effects of HCV Integrated Care (IC) for increasing treatment rates and sustained viral response (SVR) were studied with direct acting antivirals (DAA).</p><p><strong>Methods: </strong>In 2012-13, VA patients, whose screening was positive for depression, PTSD, or substance use (<i>N</i> = 79), were randomized to IC or Usual Care (UC). IC consisted of brief psychological interventions and case management. The primary endpoint was SVR among patients followed for an average of 16.6 months.</p><p><strong>Results: </strong>42% of the study participants were previously homeless and 79% had HCV genotype 1. Twice as many IC participants (45%) initiated treatment compared with UC participants (23%) (<i>χ</i><sup>2</sup> = 4.59, <i>p</i> = 0.032). Among those treated, SVR rates did not significantly differ (IC: 12/18 = 67%; UC: 5/9 = 55%; <i>p</i> = 0.23). Among all randomized participants, IC participants trended toward better SVR rates (30.0% versus 12.8% in UC; <i>p</i> = 0.07).</p><p><strong>Conclusions: </strong>Although first-generation DAAs are no longer used, this smaller RCT helps confirm the results of a larger multisite RCT showing that Integrated Care results in higher treatment initiation and SVR rates among HCV-infected persons with comorbid psychological disorders. Integrated mental health services can facilitate treatment among the most challenging HCV patients, many of whom have not been successfully treated. This trial is registered with ClinicalTrials.gov number NCT00722423.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/5834182","citationCount":"8","resultStr":"{\"title\":\"HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.\",\"authors\":\"Erik J Groessl,&nbsp;Lin Liu,&nbsp;Marisa Sklar,&nbsp;Samuel B Ho\",\"doi\":\"10.1155/2017/5834182\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Psychiatric or substance use disorders are barriers to successful HCV antiviral treatment. In a randomized, controlled trial (RCT), the effects of HCV Integrated Care (IC) for increasing treatment rates and sustained viral response (SVR) were studied with direct acting antivirals (DAA).</p><p><strong>Methods: </strong>In 2012-13, VA patients, whose screening was positive for depression, PTSD, or substance use (<i>N</i> = 79), were randomized to IC or Usual Care (UC). IC consisted of brief psychological interventions and case management. The primary endpoint was SVR among patients followed for an average of 16.6 months.</p><p><strong>Results: </strong>42% of the study participants were previously homeless and 79% had HCV genotype 1. Twice as many IC participants (45%) initiated treatment compared with UC participants (23%) (<i>χ</i><sup>2</sup> = 4.59, <i>p</i> = 0.032). Among those treated, SVR rates did not significantly differ (IC: 12/18 = 67%; UC: 5/9 = 55%; <i>p</i> = 0.23). Among all randomized participants, IC participants trended toward better SVR rates (30.0% versus 12.8% in UC; <i>p</i> = 0.07).</p><p><strong>Conclusions: </strong>Although first-generation DAAs are no longer used, this smaller RCT helps confirm the results of a larger multisite RCT showing that Integrated Care results in higher treatment initiation and SVR rates among HCV-infected persons with comorbid psychological disorders. Integrated mental health services can facilitate treatment among the most challenging HCV patients, many of whom have not been successfully treated. This trial is registered with ClinicalTrials.gov number NCT00722423.</p>\",\"PeriodicalId\":46297,\"journal\":{\"name\":\"International Journal of Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2017/5834182\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2017/5834182\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/7/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/5834182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/7/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 8

摘要

背景和目的:精神障碍或物质使用障碍是HCV抗病毒治疗成功的障碍。在一项随机对照试验(RCT)中,研究了HCV综合治疗(IC)与直接作用抗病毒药物(DAA)在提高治疗率和持续病毒反应(SVR)方面的作用。方法:2012- 2013年,筛查为抑郁、创伤后应激障碍或物质使用阳性的VA患者(N = 79)随机分为IC组或常规护理组(UC)。综合干预包括简短的心理干预和病例管理。主要终点是平均随访16.6个月的患者SVR。结果:42%的研究参与者以前无家可归,79%的人患有HCV基因型1。开始治疗的IC参与者(45%)是UC参与者(23%)的两倍(χ2 = 4.59, p = 0.032)。在治疗组中,SVR率无显著差异(IC: 12/18 = 67%;Uc: 5/9 = 55%;P = 0.23)。在所有随机参与者中,IC参与者倾向于更好的SVR率(30.0%对12.8% UC;P = 0.07)。结论:虽然第一代daa不再被使用,但这一较小的随机对照试验有助于证实一项较大的多位点随机对照试验的结果,该结果表明,综合护理在伴有共病心理障碍的hcv感染者中导致更高的治疗起始率和SVR率。综合精神卫生服务可以促进最具挑战性的丙型肝炎患者的治疗,其中许多人尚未得到成功治疗。该试验已在ClinicalTrials.gov注册,注册号为NCT00722423。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.

Background and aims: Psychiatric or substance use disorders are barriers to successful HCV antiviral treatment. In a randomized, controlled trial (RCT), the effects of HCV Integrated Care (IC) for increasing treatment rates and sustained viral response (SVR) were studied with direct acting antivirals (DAA).

Methods: In 2012-13, VA patients, whose screening was positive for depression, PTSD, or substance use (N = 79), were randomized to IC or Usual Care (UC). IC consisted of brief psychological interventions and case management. The primary endpoint was SVR among patients followed for an average of 16.6 months.

Results: 42% of the study participants were previously homeless and 79% had HCV genotype 1. Twice as many IC participants (45%) initiated treatment compared with UC participants (23%) (χ2 = 4.59, p = 0.032). Among those treated, SVR rates did not significantly differ (IC: 12/18 = 67%; UC: 5/9 = 55%; p = 0.23). Among all randomized participants, IC participants trended toward better SVR rates (30.0% versus 12.8% in UC; p = 0.07).

Conclusions: Although first-generation DAAs are no longer used, this smaller RCT helps confirm the results of a larger multisite RCT showing that Integrated Care results in higher treatment initiation and SVR rates among HCV-infected persons with comorbid psychological disorders. Integrated mental health services can facilitate treatment among the most challenging HCV patients, many of whom have not been successfully treated. This trial is registered with ClinicalTrials.gov number NCT00722423.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Hepatology
International Journal of Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
3.80
自引率
0.00%
发文量
11
审稿时长
15 weeks
期刊介绍: International Journal of Hepatology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the medical, surgical, pathological, biochemical, and physiological aspects of hepatology, as well as the management of disorders affecting the liver, gallbladder, biliary tree, and pancreas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信